Faricimab Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 6 mg/0.05 mL
Reference Brands: Vabysmo (USA/EU)
Category:
Opthalmology
Faricimab is available in Injection
and strengths such as 6 mg/0.05 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Faricimab is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Faricimab can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Faricimab (faricimab-svoa) is an advanced ophthalmic biologic therapy developed to treat serious degenerative retinal conditions that can lead to vision loss. It is a humanised bispecific monoclonal antibody designed to simultaneously target vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2), two key pathways involved in abnormal blood vessel growth, leakage, and inflammation in the retina. By blocking these mechanisms, faricimab helps stabilise blood vessels, reduce fluid accumulation, and improve visual outcomes in patients with retinal diseases.
This therapy is primarily indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular oedema (DMO), and it is also being used in the management of retinal vein occlusion-related macular oedema. Administered through intravitreal injection by an eye specialist, faricimab offers a targeted approach to controlling disease progression while protecting retinal structure and function.
One of the key advantages of faricimab is its potential to reduce treatment burden compared with traditional anti-VEGF therapies, as many patients may require fewer injections and clinic visits while maintaining effective disease control. Due to its dual-pathway inhibition and strong clinical trial outcomes, faricimab has become an important advancement in the management of complex macular diseases.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing